Visakorpi T, Kallioniemi O P, Paronen I Y, Isola J J, Heikkinen A I, Koivula T A
Department of Clinical Chemistry, Tampere University Hospital, Finland.
Br J Cancer. 1991 Sep;64(3):578-82. doi: 10.1038/bjc.1991.353.
We analysed ploidy and S-phase fraction (SPF) from 78 paraffin-embedded primary prostatic carcinomas by DNA flow cytometry. DNA aneuploidy and above median (4.2%) SPF were both associated with high tumour grade, large size of prostate and presence of distant metastases. Both aneuploidy and high SPF (greater than 4.2%) indicated short 10-year progression-free (P = 0.01 for ploidy and P = 0.0002 for SPF), overall (P = 0.004 and P less than 0.0001) as well as prostate cancer survival (P = 0.002 and P less than 0.0001). Ten-year overall survival rate was 45% in cases with SPF below 4.2% and 0% in those with higher values, whereas the corresponding prostate cancer-specific survival rates were 80% and 11%, respectively. None of the seven tumours with SPF above 12% showed an objective response to endocrine therapy, whereas 26/49 (52%) of those with lower SPF values responded (P = 0.01). DNA ploidy, tumour grade, T-stage or M-stage did not significantly correlate with endocrine responsiveness. SPF was also the best predictor of progression free survival in patients treated hormonally. In conclusion, detection of high SPF in prostate cancer may indicate lack of hormonal responsiveness and poor prognosis.
我们通过DNA流式细胞术分析了78例石蜡包埋的原发性前列腺癌的倍性和S期分数（SPF）。DNA非整倍体和高于中位数（4.2%）的SPF均与高肿瘤分级、前列腺体积大以及远处转移的存在相关。非整倍体和高SPF（大于4.2%）均表明无进展生存期短（倍性P = 0.01，SPF P = 0.0002）、总生存期短（P = 0.004和P小于0.0001）以及前列腺癌生存期短（P = 0.002和P小于0.0001）。SPF低于4.2%的病例10年总生存率为45%，而SPF值较高的病例为0%，而相应的前列腺癌特异性生存率分别为80%和11%。SPF高于12%的7例肿瘤中无一例对内分泌治疗有客观反应，而SPF值较低的病例中有26/49（52%）有反应（P = 0.01）。DNA倍性、肿瘤分级、T分期或M分期与内分泌反应性无显著相关性。SPF也是接受激素治疗患者无进展生存期的最佳预测指标。总之，前列腺癌中高SPF的检测可能表明缺乏激素反应性和预后不良。
